Samta Jain1, Bilori Bilori2, Amit Gupta3, Pete Spanos4, Mamta Singh5. 1. Internal Medicine Hospitalist for the Cleveland Clinic Foundation in OH. drsamtajain@yahoo.com. 2. Chief Resident in Internal Medicine at the Yale Waterbury Hospital in CT. bilori786@gmail.com. 3. Assistant Professor of Clinical Radiology at the Stonybrook University Hospital in NY. amitgupta0707@gmail.com. 4. Technology Specialist at Case Western Reserve University and Louis Stoke Cleveland Veterans Administration Medical Center in OH. pete.spanos@va.gov. 5. Physician Director of the Center of Excellence for the Louis Stoke Cleveland Veterans Administration Medical Center in OH. mamta.singh@va.gov.
Abstract
CONTEXT: Osteoporosis is a major cause of morbidity and mortality in both men and women. The mortality rate in men within 1 year of hip fracture is 37.5%, which is 51% higher than in women. Although clear guidelines exist for osteoporosis screening in women, these are less clear for men. The available guidelines recommend screening high-risk men; however, screening does not appear to be a standard practice. OBJECTIVE: To increase screening rates of osteoporosis in high-risk men in our primary care clinic by 50%. DESIGN: The screening rate of osteoporosis was determined in high-risk male veterans more than 50 years of age enrolled in the resident physician- and nurse practitioner-staffed primary care clinics at a Veterans Affairs Medical Center in Cleveland, OH. High-risk factors included prolonged use of steroids; hypogonadism; and autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus, which are known to be associated with osteoporosis. We surveyed health care professional trainees and nurses to explore their barriers to screening for osteoporosis in high-risk men. MAIN OUTCOME MEASURES: After creating awareness about the importance of this condition among the health care professionals, we analyzed whether this education had any impact on the screening rate. RESULTS: The baseline screening rate in high-risk men was 11%. After phased surveys and awareness building, the screening rate increased to 20%. CONCLUSION: Osteoporosis in high-risk men is under-screened. Creating more awareness about the impact of this condition among health professional trainees and nurses can lead to improved screening rates.
CONTEXT: Osteoporosis is a major cause of morbidity and mortality in both men and women. The mortality rate in men within 1 year of hip fracture is 37.5%, which is 51% higher than in women. Although clear guidelines exist for osteoporosis screening in women, these are less clear for men. The available guidelines recommend screening high-risk men; however, screening does not appear to be a standard practice. OBJECTIVE: To increase screening rates of osteoporosis in high-risk men in our primary care clinic by 50%. DESIGN: The screening rate of osteoporosis was determined in high-risk male veterans more than 50 years of age enrolled in the resident physician- and nurse practitioner-staffed primary care clinics at a Veterans Affairs Medical Center in Cleveland, OH. High-risk factors included prolonged use of steroids; hypogonadism; and autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus, which are known to be associated with osteoporosis. We surveyed health care professional trainees and nurses to explore their barriers to screening for osteoporosis in high-risk men. MAIN OUTCOME MEASURES: After creating awareness about the importance of this condition among the health care professionals, we analyzed whether this education had any impact on the screening rate. RESULTS: The baseline screening rate in high-risk men was 11%. After phased surveys and awareness building, the screening rate increased to 20%. CONCLUSION:Osteoporosis in high-risk men is under-screened. Creating more awareness about the impact of this condition among health professional trainees and nurses can lead to improved screening rates.
Authors: E Michael Lewiecki; Catherine M Gordon; Sanford Baim; Mary B Leonard; Nicholas J Bishop; Maria-Luisa Bianchi; Heidi J Kalkwarf; Craig B Langman; Horatio Plotkin; Frank Rauch; Babette S Zemel; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; Stuart Silverman Journal: Bone Date: 2008-08-15 Impact factor: 4.398
Authors: Nelson B Watts; Robert A Adler; John P Bilezikian; Matthew T Drake; Richard Eastell; Eric S Orwoll; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2012-06 Impact factor: 5.958
Authors: John T Schousboe; Brent C Taylor; Howard A Fink; Robert L Kane; Steven R Cummings; Eric S Orwoll; L Joseph Melton; Douglas C Bauer; Kristine E Ensrud Journal: JAMA Date: 2007-08-08 Impact factor: 56.272
Authors: Suzanne E Bentler; Li Liu; Maksym Obrizan; Elizabeth A Cook; Kara B Wright; John F Geweke; Elizabeth A Chrischilles; Claire E Pavlik; Robert B Wallace; Robert L Ohsfeldt; Michael P Jones; Gary E Rosenthal; Fredric D Wolinsky Journal: Am J Epidemiol Date: 2009-10-04 Impact factor: 4.897
Authors: Cathleen S Colón-Emeric; Carl F Pieper; Courtney H Van Houtven; Janet M Grubber; Kenneth W Lyles; Joanne Lafleur; Robert A Adler Journal: Mayo Clin Proc Date: 2018-12 Impact factor: 7.616
Authors: Aaron T Seaman; Melissa J A Steffen; Jennifer M Van Tiem; Shylo Wardyn; Xiomara Santana; Karla L Miller; Samantha L Solimeo Journal: Osteoporos Int Date: 2021-08-19 Impact factor: 4.507
Authors: Margaret L Gourlay; Victor S Ritter; Jason P Fine; Robert A Overman; John T Schousboe; Peggy M Cawthon; Eric S Orwoll; Tuan V Nguyen; Nancy E Lane; Steven R Cummings; Deborah M Kado; Jodi A Lapidus; Susan J Diem; Kristine E Ensrud Journal: Arch Osteoporos Date: 2017-10-20 Impact factor: 2.617